Abstract: The present invention encompasses pharmaceutical excipient complexes comprising combining at least one carrier with an oily substance, and processes for preparing the same, stable pharmaceutical compositions comprising such complexes and active pharmaceutical ingredients and processes for preparing the same.

Abstract: Stable personal care composition comprising from about 0.1% to about 15% of a non-emulsifying crosslinked siloxane elastomer; from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer; from about 1% to about 40% of an elastomer solvent; less than 0.1% of a solidifying agent; an aqueous phase comprising from about 0.0001% to about 10%, by weight of the composition, of a hydrophilic colorant; whereupon application of shear force to the composition a visibly enhanced aqueous phase is visibly separated from the non-aqueous phase.

Abstract: A novel antiseptic composition comprising an antiseptic in a carrier composition comprising nanostructures and a liquid and methods of use thereof are provided.

Abstract: Multistage delivery vehicles are disclosed which include a first stage particle and a second stage particle. The first stage particle is a micro or nanoparticle that contains the second stage particle. The second stage particle includes an active agent, such as a therapeutic agent or an imaging agent. The multistage delivery vehicle allows sequential overcoming or bypassing of biological barriers. The multistage delivery vehicle is administered as a part of a composition that includes a plurality of the vehicles. Methods of making the multistage delivery vehicles are also provided.

Abstract: The invention provides a process for preparing a dispersion of particles, by reducing in particle size at least one component by agitating the component in the presence of (i) a plurality of beads; (ii) a powder; (iii) a surfactant; and (iv) a liquid medium to form a dispersion, wherein the particles are uniformly dispersed in the liquid medium. The invention further provides for the use of the dispersion of particles.

Abstract: The present invention relates to a composition formed of metal pigments and to a process for their preparation. The composition is composed of metal particles FP and a liquid, the liquid being an ester of a fatty acid R?-COOR in which R? is a saturated or unsaturated aliphatic group having from 9 to 20 carbon atoms and R is an alkyl having from 1 to 8 carbon atoms. It is obtained by a process which consists in introducing starting particles of the metal (SP) into a liquid vehicle and in subjecting the mixture thus obtained to milling, said liquid vehicle being said fatty acid ester. Uses: preparation of paints, of inks, of plastics or of cosmetic compositions.

Abstract: A novel dosage form. The dosage form is presented in particulate form and before oral ingestion the particulate material is subjected to an aqueous medium, whereby it is converted to a semi-solid form by swelling or gelling of one or more of the components, especially of a gellan gum, of the particulate matter. The invention also relates to a vehicle for oral administration of one or more active substances, the vehicle comprising a gellan gum arranged in a configuration allowing optimal water diffusion so that upon addition of a predetermined amount of an aqueous medium, without the necessity of applying shear forces or other mixing forces, within a time period of 5 minutes or less swells and/or gels and the texture of the swelled vehicle being similar to that of a soft pudding and having a viscosity of at least about 10,000 cps as measured by a Brookfield Viscometer with a #4 LV spindle at 6 rpm and at 20-25° C.

Abstract: Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein.

Abstract: A fused solid dispersion comprising an active ingredient having a melting point of 800 C or below and a pharmaceutically acceptable absorbent having a specific surface area ranging from 20 to 400 mVg can be conveniently compressed into a tablet without generating capping and sticking problems, and a tablet comprising said fused solid dispersion can maintain an uniform release rate over a prolonged time when orally administered.

Abstract: A photosensitizer that is excitable via infrared radiation and is adapted to be used to treat a selected biological target. The photosensitizer comprises a core nanoparticle adapted to convert infrared radiation into a visible light emission, and a coating disposed about the core nanoparticle. The coating contains a light excitable agent that is adapted to be excited by the visible light emission from the core nanoparticle. The photosensitizer can be surface modified with an antibody to make the photosensitizer specific to the biological target that is to be treated. Such surface modified photosensitizer is introduced to the target site and irradiated with infrared radiation.

Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.

Abstract: The present invention relates generally to therapeutic formulations. More particularly, this present invention provides an oral delivery system for a therapeutic compound that is a base, a salt of a base or an amphoteric compound or a salt of a amphoteric compound with pharmacological, physiological or biochemical activity or a proactive form thereof. The present invention even more particularly provides a swallow formulation comprising a therapeutic compound that is a base, a salt of a base, an amphoteric compound or a salt of an amphoteric compound which facilitates the rapid delivery of the therapeutic compound to the circulatory system.

Abstract: The subject of the present invention is an anhydrous cosmetic composition in powdered form comprising at least one pulverulent phase and a fatty binder, the said pulverulent phase comprising i) 30 to 70% by weight, relative to the total weight of the composition, of at least one pigment, and ii) 30 to 70% by weight, relative to the total weight of the composition, of at least one lamellar particle. The subject of the present invention is also a method for making up the skin, comprising the application of the said composition, and its use for producing a make-up capable of concealing the colour defects of the skin, while conferring a natural and satiny appearance on the made-up skin.

Abstract: Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles.

Abstract: An object of the present invention is to prevent the generation of chlorine dioxide in a liquid preparation for ophthalmic use containing a chlorite. A liquid preparation for ophthalmic use containing a preservative composition for ophthalmic use comprising a chlorite and at least one stabilizer selected from the following 1) to 7): 1) creatinine; 2) geraniol; 3) glucose; 4) tocopherol acetate; 5) oxyquinoline sulfate; 6) a sugar alcohol; and 7) a polyoxyethylene sorbitan fatty acid ester can prevent the generation of chlorine dioxide, and is therefore excellent in safety and exhibits a sustained preservative effect for a prolonged period of time.

Abstract: An inventive flowable granular material for adhesion to foliage is provided, which material includes peanut hull fragments as a preferably majority lightweight component, a heavy weight component mixed therewith to improve the flowability of the resultant granular material, and a solvent to aid in the transfer of the foliar active agent to a leaf surface and foliar adhesion. Related particle size distributions and densities are described. Also provided is a process for promoting plant growth comprising: broadcast distributing the inventive flowable granular material to adhere to foliar surfaces; and releasing the foliar active agent onto the foliar surface.

Abstract: The invention provides novel pellets adapted for biologically active preparations and a novel process for preparing said pellets. The novel pellets are adapted for use in the delivery of a biologically active agent. The pellets have an inner zone comprising a plurality of micropellets which are bound together to form a pellet when the micropellets are dispersed in a matrix of an inert pharmaceutical excipient, a biologically active agent and optionally having an outer zone comprising a surface layer comprising a pharmaceutical excipient with or without a biologically active agent. The pellets will have an arcuate surface due to the manner in which they are formed.

Abstract: The present invention relates to topical anaesthetic compositions, uses thereof and methods for their preparation.

Abstract: A micelle formable from at least one nanotube in a process of self-assembly, the nanotube comprising an amphophilic nanotube (2, 8, 14) made from one or more species selected from the group of carbon, silicon, a noble metal, silicon dioxide and titanium dioxide. A part of the nanotube (2, 8, 14) is functionalised and a surfactant molecule or emulsifying agent is attached to the functionalised part. The nanotube (2, 8, 14) may have magnetic properties. A therapeutic agent may be incorporated in the micelle. The micelle may be coated to form a capsule (24). The capsule (24) can be introduced to the human or animal body for treatment of tumors or targeted drug delivery when a magnetic field or near-IR radiation is applied.

Abstract: The present invention relates to an improved method for treating a wide range of inflammatory disorders by administering a tetracycline compound together with an effective inhibitor of tetracycline absorption, such as polyvalent metals. Pharmaceutical compositions used in that method are also taught.

Abstract: There exists a strong desire both for pharmaceutical compositions which rapidly exhibit pharmacological effects without an increase in the size of the dosage form or a decline in quality due to interactions between a pharmaceutically active ingredient and the disintegrant, and also for a method of preparing such pharmaceutical compositions. Such a desire is especially acute with regard to, for example, preparations which contain a drug such as an analgesic or a quick-acting hypoglycemic drug that requires the rapid appearance of pharmacological effects following administration, preparations which have a high content of the pharmaceutically active ingredient, and preparations which contain two or more different pharmaceutically active ingredients.

Abstract: Arsenic in drinking water at levels between 25 and <75 ?g/L is cancer protective, compared to levels between 0 and <25 ?g/L and levels at or above 75 ?g/L. Methods are presented to decrease the cancer rate or not increase the cancer rate, for specific cancers and for cancers in general, based on this observation.

Abstract: The solid precursor is used for the preparation of a pasty bone replacement material by admixture of a liquid. The precursor comprises calcium-containing ceramic particles and a hydrogel or a substance which can be swelled into a hydrogel; whereby said precursor has been obtained by wet autoclaving and subsequent drying.

Abstract: The present invention relates to a mixture of interference pigments, where the mixture comprises at least one interference pigment A comprising a substrate and a coating comprising metallic iron, and an interference pigment B comprising a substrate and a coating comprising metallic tin and in addition at least one metal oxide, to the use thereof in cosmetics, surface coatings, inks, plastics, films, in security printing, in security features in documents and identity papers, for colouring seed, for colouring foods, for laser marking or in medicament coatings and for the preparation of pigment compositions and dry preparations, and to cosmetics, surface coatings, inks, plastics, films, documents and identity papers, seed, foods or medicament coatings, pigment compositions and dry preparations comprising the mixture according to the invention.

Abstract: A preventive/therapeutic composition for free radical diseases, characterized by containing as an active ingredient at least one kind of a fullerene, a fullerene derivative, and a composite comprising a fullerene or fullerene derivative and an organic compound with which the fullerene or derivative has been modified or clathrated. The composition is reduced in side effects, has the high ability to eliminate free radicals in the body, and further has excellent preparation stability.

Abstract: A nutritional supplement preparation is provided that includes minerals and trace elements such as vitamin D, calcium, magnesium, selenium, copper, zinc and chromium, as well as at least one catalyst and/or active ingredient, preferably in powder form, which increases and/or improves and/or accelerates the absorption of the minerals and/or trace elements.

Abstract: Application of a reducing agent followed by an oxidising agent to a nail substantially increases the permeability thereof, thereby enabling the passage of drugs across the nail.

Abstract: The present invention relates to pigments comprising a substrate and, applied thereto, an iron-containing coating comprising metallic iron, process for the preparation of the pigments according to the invention, and the use thereof.

Abstract: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is associated with the carbon nanotubes.

Abstract: A rapidly disintegrating dosage form containing magnesium carbonate heavy is described, which disintegrates upon contact with moisture. The dosage forms can be either dispersible or orodispersible tablets and can accommodate widely different active principles. The magnesium carbonate heavy is found to be an excellent dispersant under basic and neutral conditions, and gives the tablets a smooth mouth-feel.

Abstract: An object of the present invention is to provide a filler capable of exhibiting semitransparent foggy effects as in fogged glasses. The present invention provides a filler comprising: a transparent or semitransparent thin platelet-like substrate; a particle layer or coating layer (hereinafter, referred to as a first layer) which is formed on the surface of the thin platelet-like substrate and composed of a hydrous oxide, carbonate, or calcined product thereof, of at least one metal (hereinafter, referred to as a first metal) selected from the group consisting of Mg, Al, and Ca; a coating layer (hereinafter, referred to as a second layer) which coats the thin platelet-like substrate comprising the first layer formed thereon and is composed of an Si hydrous oxide or calcined product thereof; and a coating layer (hereinafter, referred to as a third layer) which coats the second layer and is composed of a Ti hydrous oxide or calcined product thereof.

Abstract: An apparatus, system, and method are disclosed for encapsulating a homeopathic ingredient with a second ingredient. A homeopathic carrier is prepared by applying the homeopathic ingredient to at least one element. The element is selected from the second ingredient, an excipient, and a capsule assembly. The second ingredient is encapsulated in a closed capsule assembly. The closed capsule assembly comprises the homeopathic carrier.

Abstract: The disclosure relates to cosmetic compositions, including makeup and care compositions for the skin, comprising at least one fatty phase comprising at least one volatile oil, at least one organic filler and at least one mineral filler, wherein the composition has: a haze index, (Th?Td)/Th*100, of greater than or equal to 40%, and a transparency index, Th, of greater than or equal to 70%, wherein Th is the hemispheric transmittance of the composition and Td is the direct transmittance of the composition. This composition may be used to mask wrinkles and other defects of the contour of the lips. It may also be used to modify the visual perception of the volume of the part of the body on which it is applied.

Abstract: A composition is provided for faster bone repair and early orthopedic implant fixation. The composition comprises an osteoinductive or osteopromotive biological factor embedded in a carrier slurry. The slurry is prepared by wetting a biodegradable polymer and calcium phosphate particles with a biocompatible fluid. The composition may be applied to the site of the bone fracture, to an orthopedic implant or to both during the surgical procedure. The composition utilizes low dosages of the biological factor and, therefore, is cost effective to be used routinely.

Abstract: A process for delivering and/or removing metal from a biological system by loading a titanate sorbent with a biometal either before introduction into the system for delivery to a site within the system or after introduction into the system for delivery to a site where there is an excess accumulation of metal and thereafter the sorbent is loaded at the site with the excess metal and is removed from the system.

Abstract: Tablet comprising at least one biologically active substance and an excipient, in which the excipient contains calcium carbonate and at least one additive selected from fatty acids, their salts, their esters, lipid materials, polysaccharides, polyvinylpyrrolidone and polyvinylpyrrolidone derivatives, acrylic compounds, mono-, di- or triglyceride esters, animal proteins, and mixtures of at least two of these. Method for producing these tablets. Use of calcium carbonate in tablets containing at least one biologically active substance, for the prolonged release of this substance.

Abstract: An eyelid scrub composition comprising polyhexamethylene biguanide (PHMB), 1,2-hexanediol, 1,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5. The composition can further comprise moisturizers and foam stabilizers. The composition can be combined with a fabric pad for use as an eyelid scrub, where the fabric pad is pre-moistened with the composition and packaged for use. The composition may be applied to the eyelid scrub and rubbed to induce foaming. The composition is produced by preparing a modified Ringer's solution and adding 1,2-hexanediol, 1,2-octanediol, and an effective amount of one or more pH stabilizing surfactants. The mixture is then heated and allowed to cool before polyhexamethylene biguanide is added.

Abstract: Disclosed are methods of inactivating a protein, such as cleaving a disulfide bond of a protein, that involve contacting the protein with a reducing agent, a denaturant, and a hydroxide ion, wherein the pH of the composition is about 10.0 to about 14.0. Also disclosed are methods of treating or preventing a disease in a subject, such as a toxin-related disease or a prion-related disease, that involve contacting a subject with a pharmaceutically effective amount of a reducing agent, a denaturant, and a hydroxide ion, wherein the pH of the composition is about 9.0 to about 14.0. Also disclosed are compositions that include a reducing agent, a denaturant, and a hydroxide ion, wherein the pH of the composition is about 9.0 to about 14.0.

Abstract: The invention relates to a cosmetic composition comprising a liquid phase and a PVD aluminum pigment, wherein the cosmetic composition contains a PVD aluminum pigment at a pigmentation level of from 0.05 to 5.0% by weight, based on the total weight of the cosmetic composition, and at least one leafing additive. The invention further relates to an artificial fingernail and to the use of a PVD aluminum pigment.

Abstract: A coating for implantable medical devices and a method for fabricating thereof are disclosed. The coating includes a mixture of a hydrophobic polymer and a polymeric hydrophilic additive, wherein the hydrophobic polymer and the hydrophilic additive form a physically entangled or interpenetrating system.

Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: The skin disinfectant, which is able to sterilize skin by the action of a surfactant without damaging skin health conditions, contains water, from which polyvalent cations are removed and to which a sodium ion is added, and a surfactant. The surfactant is, for example, a fatty acid salt. When the skin disinfectant is applied onto skin, fungi and bacteria adhered or parasitic onto skin is sterilized by the action of the surfactant. At this time, the surfactant is not likely to give an irritation to skin due to the action of the water, from which polyvalent cations are removed and to which a sodium ion is added, and thus the skin health conditions tend not to be damaged. Accordingly, the skin disinfectant is useful as a remedy for, for example, a ringworm infectious disease.

Abstract: Gold suspensions with high concentrations of gold, and silver suspensions with high concentrations of silver, are provided. Gold or silver nanoparticles are put into suspension, where the metal nanoparticles are paired with silica. Biocompatible suspensions are one application. Noble metal particles, attached to the surface of silica particles, form a stable, non-agglomerated suspension due to the steric and repulsive properties of the silica particles. The noble metal particles are prepared by activating the surface of the silica particles and erecting nucleation sites for metal particle growth, and then growing the metal particles at the nucleation sites through a reduction procedure.

Abstract: Composition, non-aerosol dispenser containing the composition, and method of raising the blood glucose level of an individual comprising administering an effective amount of the composition to an oral mucosa of the individual. The composition comprises: a. an effective amount of glucose, b. an effective amount of at least one absorption enhancer chosen from lecithin, hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening primrose oil, menthol, trihydroxy oxo cholanyl glycine, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers, polidocanol alkyl ethers, chenodeoxycholate, deoxycholate, alkali metal salicylate, pharmaceutically acceptable edetate, and pharmaceutically acceptable salts and analogues thereof, and c. an effective amount of a pharmaceutically acceptable carrier, wherein the composition is free of any active pharmaceutical agents.

Abstract: A composition contains an inorganic substance obtained as a residue after incinerating skins of marine organisms, and chitin/chitosan. The composition is obtained by incinerating the skins of the marine organisms at a temperature within a range between 600° C. and 1000° C. to obtain the inorganic substance as a residue, obtaining a powdered inorganic substance from the inorganic substance, and kneading the powdered inorganic substance with chitin/chitosan powder.

Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.

Abstract: A compressible tricalcium phosphate agglomerate comprises tricalcium phosphate particles, each having an outer surface, and a binder comprising a polyvinylpyrollidone, carrageenan, or a guar gum, supported on at least a portion of the outer surface of at least a portion of the tricalcium phosphate particles.

Abstract: The present invention relates to nimesulide topical formulations comprising a carboxyvinylpolymer neutralized as a gel-forming agent or a polyacrylamide-isoparaffin and a solvent selected from the group consisting of ethanol, isopropanol and diethylene glycol monoethyl ether, and to the process for the preparation thereof. Said formulations have advantages such as higher stability of the system and bioavailability of the active ingredient.

Abstract: This invention relates to a broad spectrum antimicrobial composition, effective against gram negative and gram positive bacteria and fungi, which comprises a synergistic composition comprising iodopropynyl butyl carbamate and a bicyclic hydroxymethyl oxazolidine containing less than 0.1% of free formaldehyde.

Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.